AIM ImmunoTech reports progress in pancreatic cancer drug trial

US-based biotechnology company AIM ImmunoTech has reported significant progress in its Phase Ib/II DURIPANC trial, which is assessing the combination of Ampligen and Imfinzi for treating late-stage pancreatic cancer patients.